Evidence-based Pragmatic Guidelines for the Follow-up of Testicular Cancer: Optimising the Detection of Relapse

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Jun 11

PMID 18542063

Citations 21

Authors

N J Van As

D C Gilbert

J Money-Kyrle

D Bloomfield

S Beesley

D P Dearnaley

A Horwich

R A Huddart

Affiliations

Soon will be listed here.

Abstract

Testicular germ cell tumours (TGCTs) are the most common cause of cancer in men between the ages of 15 and 40 years, and, overall, the majority of patients should expect to be cured. The European Germ Cell Cancer Consensus Group has provided clear guidelines for the primary treatment of both seminoma and nonseminomatous germ cell tumours. There is, however, no international consensus on how best to follow patients after their initial management. This must promptly and reliably identify relapses without causing further harm. The standardising of follow-up would result in optimising risk-benefit ratios for individual patients, while ensuring economic use of resources. We have identified the seven common scenarios in managing seminomas and nonseminomas of the various stages and discuss the pertinent issues around relapse and follow-up. We review the available literature and present our comprehensive TGCT follow-up guidelines. Our protocols provide a pragmatic, easily accessible user-friendly basis for other centres to use or to adapt to suit their needs. Furthermore, this should enable future trials to address specific issues around follow-up giving meaningful and useful results.

Citing Articles

Postpubertal-Type Teratoma of the Retroperitoneal Space as a Late Recurrence of a Testicular Germ Cell Tumor: A Case Report With Clinical Insight.

Aslanova A, Ishida M, Takahashi R, Suzuki Y, Arizono E, Wakabayashi Y Cureus. 2024; 16(10):e71667.

PMID: 39552994 PMC: 11568274. DOI: 10.7759/cureus.71667.

Unveiling the genomic landscape of possible metastatic malignant transformation of teratoma secondary to cisplatin-chemotherapy: a Tempus gene analysis-based case report literature review.

Farag C, Johnston E, Antar R, Issa S, Gadiwalla Q, Tariq Z Front Oncol. 2023; 13:1192843.

PMID: 37427132 PMC: 10324607. DOI: 10.3389/fonc.2023.1192843.

The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls.

Pierre T, Selhane F, Zareski E, Garcia C, Fizazi K, Loriot Y Cancers (Basel). 2022; 14(16).

PMID: 36010958 PMC: 9406011. DOI: 10.3390/cancers14163965.

Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors.

Gariscsak P, Anson-Cartwright L, Atenafu E, Jiang D, Chung P, Bedard P Eur Urol Open Sci. 2022; 40:46-53.

PMID: 35638085 PMC: 9142749. DOI: 10.1016/j.euros.2022.03.010.

[Follow-up of testicular germ cell tumors-historical aspects and current recommendations].

Dieckmann K, Ruf C, Gubitz R, Wulfing C, Zengerling F Urologe A. 2022; 61(5):484-494.

PMID: 35384479 DOI: 10.1007/s00120-022-01815-6.

References

Martin J, Panzarella T, Zwahlen D, Chung P, Warde P . Evidence-based guidelines for following stage 1 seminoma. Cancer. 2007; 109(11):2248-56. DOI: 10.1002/cncr.22674. View

Hoffman D, Lonstein J, Morin M, VISSCHER W, Harris 3rd B, Boice Jr J . Breast cancer in women with scoliosis exposed to multiple diagnostic x rays. J Natl Cancer Inst. 1989; 81(17):1307-12. DOI: 10.1093/jnci/81.17.1307. View

van den Belt-Dusebout A, Nuver J, de Wit R, Gietema J, Ten Bokkel Huinink W, Rodrigus P . Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006; 24(3):467-75. DOI: 10.1200/JCO.2005.02.7193. View

Gietema J, Meinardi M, Sleijfer D, Hoekstra H, van der Graaf W . Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol. 2002; 13(10):1616-20. DOI: 10.1093/annonc/mdf282. View

Oliver R, Mason M, Mead G, von der Maase H, Rustin G, Joffe J . Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366(9482):293-300. DOI: 10.1016/S0140-6736(05)66984-X. View

Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl M, Sauer R . Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003; 21(6):1101-6. DOI: 10.1200/JCO.2003.06.065. View

Brenner D . Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology. 2004; 231(2):440-5. DOI: 10.1148/radiol.2312030880. View

Arranz Arija J, Garcia Del Muro X, Guma J, Aparicio J, Salazar R, Saenz A . E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. Ann Oncol. 2001; 12(4):487-91. DOI: 10.1023/a:1011127715764. View

Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N . Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2005; 61(3):736-40. DOI: 10.1016/j.ijrobp.2004.06.209. View

10.

Hoei-Hansen C, Nielsen J, Almstrup K, Hansen M, Skakkebaek N, Rajpert-DeMeyts E . Identification of genes differentially expressed in testes containing carcinoma in situ. Mol Hum Reprod. 2004; 10(6):423-31. DOI: 10.1093/molehr/gah059. View

11.

Huddart R, Joffe J . Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol). 2006; 18(9):693-5. DOI: 10.1016/j.clon.2006.08.002. View

12.

Sonneveld D, Hoekstra H, van der Graaf W, Sluiter W, Mulder N, Willemse P . Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer. 2001; 91(7):1304-15. View

13.

Daugaard G, Petersen P, Rorth M . Surveillance in stage I testicular cancer. APMIS. 2003; 111(1):76-83; discussion 83-5. DOI: 10.1034/j.1600-0463.2003.11101111.x. View

14.

Atsu N, Eskicorapci S, Uner A, Ekici S, Gungen Y, Erkan I . A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int. 2003; 92(1):32-5. DOI: 10.1046/j.1464-410x.2003.04270.x. View

15.

Jones W, Fossa S, Mead G, Roberts J, Sokal M, Horwich A . Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005; 23(6):1200-8. DOI: 10.1200/JCO.2005.08.003. View

16.

Huddart R, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J . Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003; 21(8):1513-23. DOI: 10.1200/JCO.2003.04.173. View

17.

Harvey M, Geldart T, Duell R, Mead G, Tung K . Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer--a necessary risk?. Ann Oncol. 2002; 13(2):237-42. DOI: 10.1093/annonc/mdf032. View

18.

Chung P, Gospodarowicz M, Panzarella T, Jewett M, Sturgeon J, Tew-George B . Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol. 2004; 45(6):754-59. DOI: 10.1016/j.eururo.2004.01.020. View

19.

Read G, Stenning S, Cullen M, Parkinson M, Horwich A, Kaye S . Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992; 10(11):1762-8. DOI: 10.1200/JCO.1992.10.11.1762. View

20.

Mead G, Stenning S, Parkinson M, Horwich A, Fossa S, Wilkinson P . The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992; 10(1):85-94. DOI: 10.1200/JCO.1992.10.1.85. View